Discovery of vaccine-like recombinant SARS-CoV-2 circulating in human

For viral diseases, vaccination with live attenuated vaccine (LAV) is one of the most effective means for fighting the diseases. However, LAV occasionally overflows from vaccinated individuals circulate in the population with unforeseen consequences. Currently, SARS-CoV-2 LAVs are undergoing clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Daniel Chang, He, Cheng-Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733243/
https://www.ncbi.nlm.nih.gov/pubmed/36482293
http://dx.doi.org/10.1186/s12985-022-01945-5
_version_ 1784846325690400768
author He, Daniel Chang
He, Cheng-Qiang
author_facet He, Daniel Chang
He, Cheng-Qiang
author_sort He, Daniel Chang
collection PubMed
description For viral diseases, vaccination with live attenuated vaccine (LAV) is one of the most effective means for fighting the diseases. However, LAV occasionally overflows from vaccinated individuals circulate in the population with unforeseen consequences. Currently, SARS-CoV-2 LAVs are undergoing clinical trials. In this study, we found that the viruses isolated from Indian SARS CoV-2 infected persons may be candidate LAV-derived strains, indicating the risk of SARS-CoV-2 LAV spillover from vaccinated persons, increasing the complexity of SARS-CoV-2 detection. In addition, the property of frequent recombination of SARS-CoV-2 increases the chance of LAV virulence reversion. Therefore, how to distinguish the LAV viruses from the wild strain and how to avoid the recombination of the circulating vaccine strain and the wild strain are the challenges currently faced by SARS CoV-2 LAV development.
format Online
Article
Text
id pubmed-9733243
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-97332432022-12-10 Discovery of vaccine-like recombinant SARS-CoV-2 circulating in human He, Daniel Chang He, Cheng-Qiang Virol J Brief Report For viral diseases, vaccination with live attenuated vaccine (LAV) is one of the most effective means for fighting the diseases. However, LAV occasionally overflows from vaccinated individuals circulate in the population with unforeseen consequences. Currently, SARS-CoV-2 LAVs are undergoing clinical trials. In this study, we found that the viruses isolated from Indian SARS CoV-2 infected persons may be candidate LAV-derived strains, indicating the risk of SARS-CoV-2 LAV spillover from vaccinated persons, increasing the complexity of SARS-CoV-2 detection. In addition, the property of frequent recombination of SARS-CoV-2 increases the chance of LAV virulence reversion. Therefore, how to distinguish the LAV viruses from the wild strain and how to avoid the recombination of the circulating vaccine strain and the wild strain are the challenges currently faced by SARS CoV-2 LAV development. BioMed Central 2022-12-08 /pmc/articles/PMC9733243/ /pubmed/36482293 http://dx.doi.org/10.1186/s12985-022-01945-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Brief Report
He, Daniel Chang
He, Cheng-Qiang
Discovery of vaccine-like recombinant SARS-CoV-2 circulating in human
title Discovery of vaccine-like recombinant SARS-CoV-2 circulating in human
title_full Discovery of vaccine-like recombinant SARS-CoV-2 circulating in human
title_fullStr Discovery of vaccine-like recombinant SARS-CoV-2 circulating in human
title_full_unstemmed Discovery of vaccine-like recombinant SARS-CoV-2 circulating in human
title_short Discovery of vaccine-like recombinant SARS-CoV-2 circulating in human
title_sort discovery of vaccine-like recombinant sars-cov-2 circulating in human
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733243/
https://www.ncbi.nlm.nih.gov/pubmed/36482293
http://dx.doi.org/10.1186/s12985-022-01945-5
work_keys_str_mv AT hedanielchang discoveryofvaccinelikerecombinantsarscov2circulatinginhuman
AT hechengqiang discoveryofvaccinelikerecombinantsarscov2circulatinginhuman

Ejemplares similares